MarginsXMarginsX
Home › Markets › Health Care › LPCN

Lipocine Inc. (LPCN)

LPCN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.66
-2.92% on the day
Market cap
$18.4M
Nano cap
Revenue · 2025
$2.0M
-82.3% on 2024
Net income · 2025
-$9.6M
-487.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1535955/000149315226009411/0001493152-26-009411-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLPCN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001535955
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.0M
Net income-$9.6M
Operating income-$10.4M
Net margin-487.1%
Operating margin-524.7%
Revenue growth-82.3%
Cash$5.2M
Total assets$17.0M
P/E (computed)Net income was not positive
P/S (computed)9.3×

Warning signs

Cash runway
3.1 months
$2.6M cash at September 30, 2026
Share count, 1 year
+99.5%
2025-11-05 to 2026-11-04 · +108.3% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$462K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$2.6M cash; operating cash flow -$2.5M a quarter.Report 2026-09-30
Shares outstanding11,073,439 (2026-11-04); 5,551,931 a year earlier; 5,315,830 three years earlier.Cover page 2026-11-04
Reverse splits, 3 years1; latest on 2024-10-23Source 2024-10-23
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-02-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorTanner LLP, Salt Lake City, Utah, United StatesPCAOB Form AP 2026-03-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $462K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.3M-$666K-$1.8M$2.6MNo debt tags$3.7M10-Q 2026-11-05
Q2 2026
2026-06-30
$190K-$2.6M-$3.0M$5.0MNo debt tags$1.6M10-Q 2026-08-04
Q1 2026
2026-03-31
$119K-$3.7M-$2.3M$5.0MNo debt tags$2.0M10-Q 2026-05-07
Q4 2025
2025-12-31
$1.1M-$2.4M-$2.9M$5.2MNo debt tags$2.0M10-K 2026-03-10
Q3 2025
2025-09-30
$115K-$3.2M-$3.0M$3.9MNo debt tags$4.3M10-Q 2026-11-05
Q2 2025
2025-06-30
$623K-$2.2M-$1.9M$6.0MNo debt tags$4.2M10-Q 2026-08-04
Q1 2025
2025-03-31
$94K-$1.9M-$2.0M$3.4MNo debt tags$3.7M10-Q 2026-05-07
Q4 2024
2024-12-31
$3.5M$1.8M$1.7M$6.2MNo debt tags$11.2M10-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-02-26
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 825 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+8.9%
1 month+5.6%
3 months-17.0%
Year to date-78.7%
1 year-39.4%
From 52-week high-84.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
COCPCocrystal Pharma Inc.$0.9777-0.24%$18.8M
ATOSAtossa Therapeutics Inc.$1.93-1.53%$19.3M
QNRXQuoin Pharmaceuticals Ltd.$3.56-3.78%$17.1M
AYTUAytu BioPharma Inc.$1.82+1.68%$19.8M
CELUCelularity Inc.$0.6191-1.75%$20.1M
SHPHShuttle Pharmaceuticals Holdings Inc.$4.24-6.40%$20.2M
KTTAPasithea Therapeutics Corp.$0.5000-4.21%$16.7M
IGCIGC Pharma Inc.$0.1750-0.57%$20.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier